First Time Loading...

Chemomab Therapeutics Ltd
NASDAQ:CMMB

Watchlist Manager
Chemomab Therapeutics Ltd Logo
Chemomab Therapeutics Ltd
NASDAQ:CMMB
Watchlist
Price: 0.7399 USD 0.64% Market Closed
Updated: May 4, 2024

Chemomab Therapeutics Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Chemomab Therapeutics Ltd
Operating Income Peer Comparison

Comparables:
CLGN
KMDA
URGN
ENTX
B
BONS

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Chemomab Therapeutics Ltd
NASDAQ:CMMB
Operating Income
-$25.5m
CAGR 3-Years
-32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Operating Income
-$6.6m
CAGR 3-Years
-6%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Operating Income
$10.1m
CAGR 3-Years
-19%
CAGR 5-Years
-12%
CAGR 10-Years
11%
Urogen Pharma Ltd
NASDAQ:URGN
Operating Income
-$65.5m
CAGR 3-Years
20%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Operating Income
-$8.9m
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Operating Income
-₪32.9m
CAGR 3-Years
-22%
CAGR 5-Years
-14%
CAGR 10-Years
-13%

See Also

What is Chemomab Therapeutics Ltd's Operating Income?
Operating Income
-25.5m USD

Based on the financial report for Dec 31, 2023, Chemomab Therapeutics Ltd's Operating Income amounts to -25.5m USD.

What is Chemomab Therapeutics Ltd's Operating Income growth rate?
Operating Income CAGR 3Y
-32%

Over the last year, the Operating Income growth was 11%. The average annual Operating Income growth rates for Chemomab Therapeutics Ltd have been -32% over the past three years .